Drug Profile
212 Pb ontuxizumab conjugate - Orano Med/Eisai Inc
Alternative Names: 212-Pb ontuxizumab conjugate - Orano Med/Morphotek; 212-Pb radioimmunotherapy - Orano Med/Morphotek; Alpha radioimmunotherapy - Orano Med/Morphotek; Lead-212 radioimmunotherapy - Orano Med/MorphotekLatest Information Update: 01 Sep 2023
Price :
$50
*
At a glance
- Originator AREVA Med; Morphotek
- Developer Eisai Inc; Orano Med
- Class Drug conjugates; Lead radioisotopes; Radiopharmaceuticals
- Mechanism of Action Ionising radiation emitters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 01 Sep 2023 Discontinued - Preclinical for Solid tumours in USA (Parenteral) (before September 2023) (Orano Med Pipeline, September 2023)
- 28 Apr 2020 No recent reports of development identified for preclinical development in Solid-tumours in USA (Parenteral)
- 31 Mar 2016 AREVA and Morphotek agree to evaluate the safety and efficacy profile of ontuxizumab conjugated with lead-212 (212Pb) in USA for Cancer